X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3918) 3918
Newsletter (52) 52
Book Chapter (19) 19
Newspaper Article (14) 14
Conference Proceeding (4) 4
Magazine Article (3) 3
Dissertation (2) 2
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3539) 3539
capecitabine (3493) 3493
science & technology (2924) 2924
life sciences & biomedicine (2872) 2872
deoxycytidine - analogs & derivatives (2716) 2716
female (2637) 2637
fluorouracil - analogs & derivatives (2485) 2485
oncology (2364) 2364
middle aged (2236) 2236
deoxycytidine - administration & dosage (2184) 2184
aged (2115) 2115
antineoplastic combined chemotherapy protocols - therapeutic use (2036) 2036
fluorouracil - administration & dosage (1992) 1992
male (1917) 1917
adult (1706) 1706
treatment outcome (1262) 1262
chemotherapy (1154) 1154
cancer (1055) 1055
antineoplastic combined chemotherapy protocols - adverse effects (944) 944
deoxycytidine - adverse effects (908) 908
breast neoplasms - drug therapy (827) 827
organoplatinum compounds - administration & dosage (763) 763
fluorouracil - adverse effects (762) 762
colorectal neoplasms - drug therapy (733) 733
aged, 80 and over (723) 723
deoxycytidine - therapeutic use (671) 671
colorectal cancer (670) 670
disease-free survival (659) 659
care and treatment (658) 658
capecitabine - administration & dosage (609) 609
neoplasm staging (603) 603
antineoplastic combined chemotherapy protocols - administration & dosage (560) 560
breast cancer (558) 558
fluorouracil - therapeutic use (558) 558
antimetabolites, antineoplastic - administration & dosage (544) 544
metastasis (542) 542
drug administration schedule (532) 532
breast neoplasms - pathology (526) 526
pharmacology & pharmacy (521) 521
medicine & public health (508) 508
research (493) 493
neoplasm metastasis (489) 489
antimetabolites, antineoplastic - therapeutic use (461) 461
administration, oral (452) 452
oxaliplatin (444) 444
retrospective studies (435) 435
antimetabolites, antineoplastic - adverse effects (426) 426
adenocarcinoma - drug therapy (423) 423
survival rate (422) 422
colorectal neoplasms - pathology (408) 408
drug therapy (408) 408
hematology, oncology and palliative medicine (381) 381
stomach neoplasms - drug therapy (375) 375
prognosis (372) 372
bevacizumab (371) 371
camptothecin - analogs & derivatives (367) 367
clinical trials (353) 353
survival analysis (348) 348
antineoplastic agents (344) 344
chemotherapy, adjuvant (337) 337
antimitotic agents (326) 326
follow-up studies (325) 325
camptothecin - administration & dosage (319) 319
taxoids - administration & dosage (313) 313
cisplatin - administration & dosage (306) 306
cancer research (304) 304
dosage and administration (299) 299
leucovorin - administration & dosage (297) 297
antineoplastic agents - therapeutic use (295) 295
dose-response relationship, drug (289) 289
prospective studies (285) 285
analysis (281) 281
patients (280) 280
combined modality therapy (270) 270
surgery (269) 269
health aspects (265) 265
toxicity (262) 262
kaplan-meier estimate (259) 259
disease progression (258) 258
adenocarcinoma - pathology (256) 256
stomach neoplasms - pathology (256) 256
cancer therapies (250) 250
antineoplastic agents - administration & dosage (249) 249
pharmacology/toxicology (246) 246
neoadjuvant therapy (240) 240
capecitabine - adverse effects (239) 239
radiotherapy (239) 239
antibodies, monoclonal, humanized (235) 235
oncology, experimental (233) 233
liver neoplasms - secondary (232) 232
5-fluorouracil (231) 231
rectal neoplasms - pathology (222) 222
antibodies, monoclonal, humanized - administration & dosage (220) 220
liver neoplasms - drug therapy (218) 218
antibodies, monoclonal - administration & dosage (216) 216
organoplatinum compounds - adverse effects (215) 215
young adult (215) 215
cancer patients (214) 214
rectal neoplasms - drug therapy (206) 206
irinotecan (201) 201
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3812) 3812
Japanese (138) 138
Chinese (44) 44
French (28) 28
German (21) 21
Russian (17) 17
Spanish (12) 12
Italian (11) 11
Portuguese (6) 6
Hungarian (5) 5
Czech (4) 4
Danish (3) 3
Dutch (3) 3
Korean (2) 2
Norwegian (2) 2
Arabic (1) 1
Hebrew (1) 1
Lithuanian (1) 1
Persian (1) 1
Polish (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 05/2019, Volume 393, Issue 10184, pp. 1948 - 1957
Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Capecitabine - administration & dosage | Leucovorin - administration & dosage | Adenocarcinoma - pathology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Oxaliplatin - therapeutic use | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Fluorouracil - therapeutic use | Docetaxel - administration & dosage | Fluorouracil - administration & dosage | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Oxaliplatin - administration & dosage | Administration, Oral | Esophagogastric Junction - pathology | Treatment Outcome | Capecitabine - therapeutic use | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Digestive System Surgical Procedures | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Docetaxel - therapeutic use | Aged | Neoplasm Staging | Adenocarcinoma | Anthracyclines | Chemotherapy | Leucovorin | Product development | Esophageal cancer | Cancer | Intravenous administration | Control methods | Toxicity | Clinical trials | Oncology | Metastasis | Cancer therapies | Stomach cancer | Evidence-based medicine | Metastases | Confidence intervals | Infusion | Oxaliplatin | Surgery | Intravenous infusion | Epirubicin | Medical research | Survival | Patients | Cisplatin | Esophagus | Interactive systems | Medical prognosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 23, pp. 3786 - 3793
Purpose Data concerning the prevalence of and outcomes related to thromboembolic events (TEs) in patients with advanced gastroesophageal cancer who are... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Anticoagulants - administration & dosage | Thromboembolism - chemically induced | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - pathology | Epirubicin - administration & dosage | Thromboembolism - epidemiology | Warfarin - administration & dosage | Antimetabolites, Antineoplastic - administration & dosage | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Incidence | Esophageal Neoplasms - complications | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Odds Ratio | Catheterization, Central Venous - adverse effects | Stomach Neoplasms - complications | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Esophagogastric Junction - pathology | Thromboembolism - etiology | Stomach Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Cisplatin - adverse effects | Aged | Esophageal Neoplasms - drug therapy | United Kingdom - epidemiology | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Journal Article
Cancer research (Chicago, Ill.), ISSN 1538-7445, 12/2011, Volume 72, Issue 3, pp. 779 - 789
The protein kinase BRAF is a key component of the RAS-RAF signaling pathway which plays an important role in regulating cell proliferation, differentiation,... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Erlotinib Hydrochloride | Area Under Curve | Capecitabine | Colorectal Neoplasms - genetics | Humans | Indoles - administration & dosage | Bevacizumab | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Indoles - pharmacology | Quinazolines - administration & dosage | Phosphorylation - drug effects | Cetuximab | Proto-Oncogene Proteins B-raf - metabolism | Camptothecin - analogs & derivatives | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | HCT116 Cells | Kaplan-Meier Estimate | Sulfonamides - pharmacology | Blotting, Western | Sulfonamides - pharmacokinetics | HT29 Cells | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Proto-Oncogene Proteins B-raf - genetics | Cell Line, Tumor | Indoles - pharmacokinetics | Cell Proliferation - drug effects | Mice | Mutation | Colorectal Neoplasms - pathology | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Drug Resistance, Neoplasm - drug effects | Mitogen-Activated Protein Kinases - metabolism | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2012, Volume 366, Issue 4, pp. 310 - 320
The addition of bevacizumab to neoadjuvant combination chemotherapy significantly increased the percentage of patients with a pathological complete response.... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bevacizumab | Angiogenesis Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Mastectomy, Segmental | Adult | Female | Neoadjuvant Therapy | Angiogenesis Inhibitors - adverse effects | Doxorubicin - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Logistic Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease Progression | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Receptor, ErbB-2 | Deoxycytidine - analogs & derivatives | Drugs | Chemotherapy | Usage | Patient outcomes | Breast cancer | Product/Service Evaluations | Drug therapy | Cancer | Heart | Mucositis | Gemcitabine | Review boards | Body weight | Cancer therapies | Antimetabolites | Doxorubicin | ErbB-2 protein | Patients | Feet | Metastases | Cyclophosphamide | Epidermal growth factor | Ventricle | Taxanes | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 829 - 840
Summary Background We aimed to assess the efficacy and safety of sequential or simultaneous telomerase vaccination (GV1001) in combination with chemotherapy in... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Cell Proliferation | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Fatigue - chemically induced | Pain - chemically induced | Pancreatic Neoplasms - drug therapy | Fluorouracil - administration & dosage | Female | Neutropenia - chemically induced | Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage | Fluorouracil - analogs & derivatives | Cancer Vaccines - administration & dosage | Deoxycytidine - administration & dosage | Pancreatic Ducts | Pancreatic Neoplasms - pathology | Peptide Fragments - administration & dosage | Immunologic Factors - administration & dosage | Kaplan-Meier Estimate | Cancer Vaccines - adverse effects | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Telomerase - administration & dosage | Disease-Free Survival | Telomerase - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | T-Lymphocytes - immunology | Aged | Peptide Fragments - adverse effects | Deoxycytidine - analogs & derivatives | Care and treatment | Chemotherapy | Hospitals | Gemcitabine | Peptides | Pancreatic cancer | Vaccination | Product development | Vaccines | Metastasis | Telomerase | Cancer | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9742, pp. 687 - 697
Journal Article
Journal Article